Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rein TherapeuticsRNTX -2.23%30 EV-to-FCF is -4.79 as of Jul. 16, 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 334 Biotechnology companies, Rein Therapeutics ranks worse than 299400.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rein Therapeutics's Enterprise Value is $79.61 Mil.
Rein Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.61 Mil. Therefore, Rein Therapeutics's EV-to-FCF for today is -4.79.
The historical rank and industry rank for Rein Therapeutics's EV-to-FCF or its related term are showing as below:
RNTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.97 Med: 0 Max: 0
Current: -4.79
RNTX's EV-to-FCF is ranked worse than 100% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs RNTX: -4.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rein Therapeutics (NAS:RNTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rein Therapeutics's PE Ratio (TTM) for today is calculated as:
Rein Therapeutics's share price for today is $0.9251.
Rein Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rein Therapeutics EV-to-FCF Related Terms
Rein Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Rein Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rein Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's EV-to-FCF falls into.
Rein Therapeutics's current Enterprise Value is $79.61 Mil.
Rein Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rein Therapeutics (RNTX) has a EV-to-FCF of -4.79 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #999999 out of 334 companies in the Biotechnology industry.
Is Rein Therapeutics' EV-to-FCF too high?
Rein Therapeutics' current EV-to-FCF is -4.79. Based on the distribution chart, Rein Therapeutics ranks #999999 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' EV-to-FCF compare to IBIO and RANI?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #999999 out of 334 companies for EV-to-FCF. This places Rein Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rein Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rein Therapeutics's current EV-to-FCF is -4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current EV-to-FCF of -4.79. The current EV-to-FCF is -4.79. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current EV-to-FCF is -4.79 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score
Get the complete analysis for RNTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
